BioCentury | Sep 30, 2013
Finance

Broader minded in Canada

Broader minded in Canada With C$135 million ($131 million) for its second healthcare fund, the venture arm of the Business Development Bank of Canada is hoping to achieve top quartile returns so that when BDC...
BioCentury | Sep 23, 2013
Finance

Quebec engine

Quebec engine Drawn by an experienced management team and the low cost of doing business in Montreal, Sanderling Ventures launched Therillia Development Co. Inc. to manage early stage development of assets to be funded by...
BC Week In Review | Jun 25, 2012
Company News

Flexion Therapeutics management update

Flexion Therapeutics Inc. , Woburn, Mass.   Business: Musculoskeletal   Hired: Arthur Fratamico as CBO, a newly created position, formerly CBO of Gemin X Pharmaceuticals Inc. , which Cephalon Inc. acquired; Teva Pharmaceuticals Industries Ltd. subsequently acquired...
BioCentury | Apr 16, 2012
Finance

Heeding health economics

Heeding health economics H.I.G. BioVentures closed an oversubscribed second fund of $268 million last week, topping its $250 million target and its $150 million 2005 fund. Like the first fund, the new fund will focus...
BioCentury | Feb 27, 2012
Finance

Caxton team to Valence

Caxton team to Valence The founders of Caxton Advantage Venture Partners are leaving to start a new firm, Valence Life Sciences . Rachel Leheny and Eric Roberts started Caxton Advantage in 2006 as part of hedge...
BioCentury | Aug 15, 2011
Product Development

Powering down cancer

The cancer metabolism field has been heating up over the last five years, and now is beginning to produce some of the first data for compounds aimed at stunting aerobic glycolysis, the energy-generating process that...
BC Week In Review | Jun 13, 2011
Clinical News

Obatoclax: Phase II data

An open-label, international Phase II trial in 155 patients showed that IV obatoclax plus carboplatin and etoposide missed the primary endpoint of significantly improving ORR vs. carboplatin and etoposide (64.9% vs. 53.8%, p=0.11). On secondary...
BC Extra | Jun 8, 2011
Clinical News

Obatoclax to enter Phase III despite Phase II miss

Cephalon Inc. (NASDAQ:CEPH) plans to begin Phase III testing of obatoclax in 1Q12 despite data showing that the product missed the primary endpoint in a Phase II trial in 155 patients with extensive-stage small cell...
BC Week In Review | Apr 18, 2011
Company News

Trevena management update

Trevena Inc. , King of Prussia, Pa.   Business: Cardiovascular, Neurology, Autoimmune   Hired: Arthur Fratamico as CBO, formerly CBO of Gemin X Pharmaceuticals Inc. , which is being acquired by Cephalon Inc.  ...
BC Week In Review | Apr 4, 2011
Company News

Cephalon, ChemGenex Pharmaceuticals deal

Cephalon will acquire the 72.4% of cancer company ChemGenex it does not already own for about A$159 million ($163 million) in cash. The deal, which comprises A$0.70 per share and A$0.02 per option, values ChemGenex...
Items per page:
1 - 10 of 76
BioCentury | Sep 30, 2013
Finance

Broader minded in Canada

Broader minded in Canada With C$135 million ($131 million) for its second healthcare fund, the venture arm of the Business Development Bank of Canada is hoping to achieve top quartile returns so that when BDC...
BioCentury | Sep 23, 2013
Finance

Quebec engine

Quebec engine Drawn by an experienced management team and the low cost of doing business in Montreal, Sanderling Ventures launched Therillia Development Co. Inc. to manage early stage development of assets to be funded by...
BC Week In Review | Jun 25, 2012
Company News

Flexion Therapeutics management update

Flexion Therapeutics Inc. , Woburn, Mass.   Business: Musculoskeletal   Hired: Arthur Fratamico as CBO, a newly created position, formerly CBO of Gemin X Pharmaceuticals Inc. , which Cephalon Inc. acquired; Teva Pharmaceuticals Industries Ltd. subsequently acquired...
BioCentury | Apr 16, 2012
Finance

Heeding health economics

Heeding health economics H.I.G. BioVentures closed an oversubscribed second fund of $268 million last week, topping its $250 million target and its $150 million 2005 fund. Like the first fund, the new fund will focus...
BioCentury | Feb 27, 2012
Finance

Caxton team to Valence

Caxton team to Valence The founders of Caxton Advantage Venture Partners are leaving to start a new firm, Valence Life Sciences . Rachel Leheny and Eric Roberts started Caxton Advantage in 2006 as part of hedge...
BioCentury | Aug 15, 2011
Product Development

Powering down cancer

The cancer metabolism field has been heating up over the last five years, and now is beginning to produce some of the first data for compounds aimed at stunting aerobic glycolysis, the energy-generating process that...
BC Week In Review | Jun 13, 2011
Clinical News

Obatoclax: Phase II data

An open-label, international Phase II trial in 155 patients showed that IV obatoclax plus carboplatin and etoposide missed the primary endpoint of significantly improving ORR vs. carboplatin and etoposide (64.9% vs. 53.8%, p=0.11). On secondary...
BC Extra | Jun 8, 2011
Clinical News

Obatoclax to enter Phase III despite Phase II miss

Cephalon Inc. (NASDAQ:CEPH) plans to begin Phase III testing of obatoclax in 1Q12 despite data showing that the product missed the primary endpoint in a Phase II trial in 155 patients with extensive-stage small cell...
BC Week In Review | Apr 18, 2011
Company News

Trevena management update

Trevena Inc. , King of Prussia, Pa.   Business: Cardiovascular, Neurology, Autoimmune   Hired: Arthur Fratamico as CBO, formerly CBO of Gemin X Pharmaceuticals Inc. , which is being acquired by Cephalon Inc.  ...
BC Week In Review | Apr 4, 2011
Company News

Cephalon, ChemGenex Pharmaceuticals deal

Cephalon will acquire the 72.4% of cancer company ChemGenex it does not already own for about A$159 million ($163 million) in cash. The deal, which comprises A$0.70 per share and A$0.02 per option, values ChemGenex...
Items per page:
1 - 10 of 76